newsfilter
← Latest News
GlobeNewswire·

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the